Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CALA $14.67 1.3600 +10.22%
ARQL $2.19 0.1500 +7.35%
ADXS $11.90 0.8000 +7.21%
AVEO $1.50 0.0800 +5.63%
CBMG $33.99 1.6000 +4.94%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BLRX $2.12 -0.6900 -24.56%
ONCY $0.90 -0.1492 -14.21%
CRIS $3.04 -0.2900 -8.71%
GERN $3.50 -0.2800 -7.41%
CVM $1.06 -0.0800 -7.02%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

MD Anderson Studies Skin Cancer Patients Resistant to Leading Therapy

(MD Anderson) Feb 23, 2015 - Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein’s power to spur cancer cell growth.
read press release 

Why Some Cancer Centers Offer Yoga to Their Patients

(ABC News) Feb 24, 2015 - A new hospital program dispenses downward dogs and tree poses to help kids with aggressive forms of cancer deal with their illnesses.
read article 

Oncologists Need to Ask About Herbs and Supplements

(Medscape Medical News) Feb 23, 2015 - A new survey shows that only 26% of US oncologists ever initiate discussions about the use of herbs and other supplements, even though they are widely used.
read article (free registration required) 

Cancer Genetics Inc to Present New Data on Identification of Genomic Changes That Predict Both Metastasis and Site of Metastasis in Kidney Cancer at the 2015 ASCO Genitourinary Cancers Symposium

(Yahoo! Finance) Feb 24, 2015 - Cancer Genetics Inc, an emerging leader in DNA-based cancer diagnostics, announced today that it has identified genomic signatures that can differentiate those patients with clear cell renal carcinoma (ccRCC) whose disease is likely to relapse or metastasize.
read article 

Data Presented at 2015 ASCO Genitourinary Symposium Compares, Validates and Demonstrates Utility for GenomeDx’s Decipher® Test

(GenomeDx) Feb 24, 2015 – GenomeDx Biosciences today announced that data to be presented at the 2015 ASCO Genitourinary Symposium demonstrates that its Decipher® Prostate Cancer Classifier was able to accurately identify patients with a high probability of metastasis-free survival despite being identified as high risk by standard risk assessment tools.
read corporate press release 

GenomeDx’s Decipher® Shows Broad Applicability in Advancing Prostate Cancer Care in Data Presented at 2015 ASCO Genitourinary Symposium

(GenomeDx) Feb 24, 2015 – Results from three new studies highlight data on the combination of genomic markers with MRI for improved diagnosis, and the identification of prostate cancer patient subtypes that may influence response to treatment at different stages of the disease.
read corporate press release 

Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab at the 2015 Genitourinary Cancers Symposium

(Morningstar) Feb 24, 2015 - Approximately 20% of men with advanced prostate cancer treated with PROSTVAC and Ipilimumab remain alive at 80 months after initiating treatment.
read article 

Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy

(ASCO) Feb 23, 2015 - Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC).
read press release 

New Screening Tests for Hard-to-Spot Breast Cancers

(Wall Street Journal) Feb 23, 2015 - For women with dense tissue, mammograms can be less accurate so new tests offer better detection but often more false alarms.
read article (paid subscription required) 

Testicular Cancer Ups Rates of Risky Prostate Cancer Later On

(Medscape Medical News) Feb 24, 2015 - Men with a history of testicular cancer not only have a greater risk of developing prostate cancer, the disease is more likely to be of intermediate to high risk when it does develop, a registry analysis shows.
read article (free registration required) 

FDA Approves Farydak (Panobinostat) For The Treatment Of Relapsed Multiple Myeloma

(The Myeloma Beacon) Feb 23, 2015 - The U.S. Food and Drug Administration (FDA) has approved panobinostat, which will be marketed under the brand name Farydak, for the treatment of relapsed and refractory multiple myeloma.
read article 

Novartis Blood Cancer Drug Wins U.S. OK After Setback

(Reuters) Feb 23, 2015 - The U.S. Food and Drug Administration on Monday approved Novartis AG's drug to treat patients who have relapsed after earlier therapies for multiple myeloma, an aggressive blood cancer, even though an advisory panel in November recommended against approval.
read article 

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer

(ASCO) Feb 23, 2015 - Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib.
read press release 

Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival

(ASCO) Feb 23, 2015 - An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis.
read press release 

Novartis Receives FDA Approval of Farydak(R), the First HDAC Inhibitor for Patients with Multiple Myeloma

(MarketWatch) Feb 23, 2015 - Novartis announced today that the US Food and Drug Administration (FDA) has approved Farydak(R) (panobinostat, previously known as LBH589) capsules in combination with bortezomib* and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory (IMiD) agent.
read article 

Valeant to Buy Salix in $10.1 Billion Deal

(Fox Business/Reuters) Feb 23, 2015 - Canada's Valeant Pharmaceuticals International Inc agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday.
read article 

FDA Says It Knew Scopes That Allegedly Spread 'Superbug' Could Transmit Bacterial Infections

(ABC News) Feb 23, 2015 - The revelation that contaminated endoscopes were cleaned according to manufacturer instructions but still allegedly caused seven people to become infected with a deadly drug-resistant bacteria has raised questions about whether the scopes are too difficult to clean.
read article 

Is There Still a Place for the Mighty Pharmaceutical Sales Force?

(BioPharma Dive) Feb 23, 2015 - For the better part of the last decade, the diminishing role of the pharmaceutical sales representative as an integral part of the pharmaceutical sales model has been a hot topic.
read article 

Merck to Team With NGM to Develop Diabetes, Obesity Treatments

(Wall Street Journal) Feb 23, 2015 - Merck & Co. Inc. said Monday that it has entered a five-year collaboration with NGM Biopharmaceuticals Inc. to research and develop drugs that treat diabetes and obesity, in the drug company’s latest bid to introduce new products.
read article (paid subscription required) 

Need to Curtail Smoking Becomes More Acute as Its Known Dangers Widen

(New York Times/Well blog) Feb 23, 2015 - A study linking an extra five diseases and 60,000 deaths to tobacco use, and the popularity of e-cigarettes, should push the F.D.A. into action.
read article 

Lilly Long-acting Insulin Delayed by Liver Concerns

(Reuters) Feb 23, 2015 - Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug.
read article 

Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung Cancer Among Neediest Communities in Central Savannah River Area

(Bristol-Myers Squibb) Feb 23, 2015 - The Bristol-Myers Squibb Foundation today announced a three-year, $1.74 million grant to the GRU Cancer Center for a pilot program to reduce the burden of lung cancer among underserved populations in Georgia’s Central Savannah River Area (CSRA).
read corporate press release 

UM Comprehensive Cancer Center Names New Director

(Crain's Detroit Business) Feb 20, 2015 - The appointment of Theodore Lawrence, M.D., as director of the University of Michigan Comprehensive Cancer Center was approved Thursday by the school’s board of regents.
read article 

Novartis AG Wins Approval to Buy GSK Cancer Drugs with Conditions

(Reuters) Feb 23, 2015 - Novartis AG has won U.S. antitrust approval to buy GlaxoSmithKline’s oncology drugs with conditions, the Federal Trade Commission said on Monday.
read article 

Heart Health After Cancer: A Growing Concern

(Forbes) Feb 23, 2015 - As cancer patients survive longer they face additional health problems. Radiation to the chest, chemotherapy, antibody therapy and hormone changes can affect blood vessels and heart function in the short term and long, during treatment or years later.
read article